The Company expects that its cash, cash equivalents and marketable securities as of December 31, 2024, will enable it to fund its operating plan into mid-2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics reports Q4 EPS (37c), consensus (44c)
- Neumora Therapeutics, Inc. (NMRA) Q4 Earnings Cheat Sheet
- Neumora Therapeutics price target lowered to $4 from $20 at Mizuho
- Positive Prospects for Neumora Therapeutics: Buy Rating Supported by Leadership Change and Strategic R&D Focus
- Neumora Therapeutics Announces Leadership Changes and Strategy